Suscribirse

Chlorhexidine gluconate does not result in epidermal microbiota dysbiosis in healthy adults - 25/05/21

Doi : 10.1016/j.ajic.2020.11.021 
Timothy L Wiemken, PhD, MPH, FAPIC, FSHEA, CIC a, b, c, , Aaron C Ericsson, DVM, PhD d, e
a Saint Louis University Department of Health and Clinical Outcomes Research, Saint Louis, MO 
b Saint Louis University Department of Medicine, Division of Infectious Diseases, Allergy, and Immunology, Saint Louis, MO 
c Saint Louis University Institute for Vaccine Science and Policy Systems Infection Prevention Center, Saint Louis, MO 
d University of Missouri Department of Veterinary Pathobiology, Columbia, MO 
e University of Missouri Metagenomics Center, Columbia, MO 

Address correspondence to Timothy Wiemken, PhD, MPH, FAPIC, FSHEA, CIC, Saint Louis University, Department of Health and Clinical Outcomes Research, Department of Medicine, Division of Infectious Diseases, Allergy, and Immunology, Director, AHeaD Institute Systems Infection Prevention Center, 3545 Lafayette Ave #411, St. Louis, MO 63104.Saint Louis UniversityDepartment of Health and Clinical Outcomes Research, Department of Medicine, Division of Infectious Diseases, Allergy, and Immunology, Director, AHeaD Institute Systems Infection Prevention Center3545 Lafayette Ave #411St. LouisMO63104

Highlights

We assessed the CHG exposure impact on the epidermal microbiota.
The microbiota showed no greater change 30 minutes postexposure to CHG.
Single applications of CHG cause minimal, if any, disruption of the epidermal microbiota.
Long-term effects of single applications of CHG on the epidermal microbiota are unlikely.

El texto completo de este artículo está disponible en PDF.

Resumen

Background

Chlorhexidine gluconate (CHG) and other skin antiseptics are ubiquitous in healthcare settings and are routinely used to bathe patients’ skin. The commensal epidermal microbiota is believed to provide colonization resistance and other benefits to the host; yet little is known regarding the long-term stability of the epidermal microbiota, and the impact of CHG bathing. We aimed to assess the influence of CHG exposure to the epidermal microbiota and evaluate the long-term stability of the epidermal microbiota.

Methods

The epidermal microbiota of 5 individuals was sampled using thorough swabbing of the calf, and characterized via 16S rRNA amplicon sequencing, prior to CHG bathing, and then at 30 minutes, 3 hours, 1 day, 3 days, and 7 days postbathing. Roughly 4 months later, samples were collected from the same 5 individuals, using an identical timeline but with no CHG exposure.

Results

The epidermal microbiota showed no greater change 30 minutes postexposure to CHG, than was observed in the same individuals during the recovery period, likely representing the normal sample-to-sample variability. Despite that variability, the epidermal microbiota evinced a remarkable degree of intrasubject stability, even over extended periods of time.

Conclusion

We conclude that single applications of CHG cause minimal, if any, disruption of the epidermal microbiota, and that long-term effects of single applications of CHG on the epidermal microbiota are unlikely.

El texto completo de este artículo está disponible en PDF.

Key Words : Antiseptic, Healthcare-associated infection, Metagenomics, Microbiome, Skin


Esquema


 Conflicts of interest: TLW is a consultant for Medline Industries.
 This study was funded via an investigator-initiated grant from Medline Industries, Deerfield, IL. Medline Industries also provided 2% chlorhexidine gluconate skin antiseptic wipes for the study. The sponsor did not play a role in conduct of the study, data analysis, or manuscript writing/review/decision to submit.


© 2020  Association for Professionals in Infection Control and Epidemiology, Inc.. Publicado por Elsevier Masson SAS. Todos los derechos reservados.
Añadir a mi biblioteca Eliminar de mi biblioteca Imprimir
Exportación

    Exportación citas

  • Fichero

  • Contenido

Vol 49 - N° 6

P. 769-774 - juin 2021 Regresar al número
Artículo precedente Artículo precedente
  • Implementation of an external female urinary catheter as an alternative to an indwelling urinary catheter
  • Curtis Warren, Jaclyn D. Fosnacht, Elizabeth E. Tremblay
| Artículo siguiente Artículo siguiente
  • Implementing daily chlorhexidine gluconate (CHG) bathing in VA settings: The human factors engineering to prevent resistant organisms (HERO) project
  • Mary Jo Knobloch, Jackson S. Musuuza, Linda McKinley, Michele L. Zimbric, Kelsey Baubie, Ann Schoofs Hundt, Pascale Carayon, Mary Hagle, Christopher D. Pfeiffer, Marinella D. Galea, Christopher J Crnich, Nasia Safdar

Bienvenido a EM-consulte, la referencia de los profesionales de la salud.
El acceso al texto completo de este artículo requiere una suscripción.

¿Ya suscrito a @@106933@@ revista ?

@@150455@@ Voir plus

Mi cuenta


Declaración CNIL

EM-CONSULTE.COM se declara a la CNIL, la declaración N º 1286925.

En virtud de la Ley N º 78-17 del 6 de enero de 1978, relativa a las computadoras, archivos y libertades, usted tiene el derecho de oposición (art.26 de la ley), el acceso (art.34 a 38 Ley), y correcta (artículo 36 de la ley) los datos que le conciernen. Por lo tanto, usted puede pedir que se corrija, complementado, clarificado, actualizado o suprimido información sobre usted que son inexactos, incompletos, engañosos, obsoletos o cuya recogida o de conservación o uso está prohibido.
La información personal sobre los visitantes de nuestro sitio, incluyendo su identidad, son confidenciales.
El jefe del sitio en el honor se compromete a respetar la confidencialidad de los requisitos legales aplicables en Francia y no de revelar dicha información a terceros.


Todo el contenido en este sitio: Copyright © 2026 Elsevier, sus licenciantes y colaboradores. Se reservan todos los derechos, incluidos los de minería de texto y datos, entrenamiento de IA y tecnologías similares. Para todo el contenido de acceso abierto, se aplican los términos de licencia de Creative Commons.